Synthesis, Antioxidant, and Antidiabetic Activities of Ketone Derivatives of Succinimide
Table 1
The percent inhibition of ABTS and DPPH of synthesized compounds.
Compound
Conc. (µg/ml)
(%) ABTS inhibitions
IC50 (μg/ml)
(%) DPPH inhibitions
IC50 (μg/ml)
BW1
500
78.35 ± 0.23
9.40
85.83 ± 0.47
10.84
250
73.36 ± 0.84
77.23 ± 0.96
125
70.62 ± 0.25
67.33 ± 0.55
62.50
66.16 ± 0.16
72.29 ± 0.57
31.25
55.67 ± 0.32
62.03 ± 0.77
BW2
500
76.85 ± 2.24
12.87
75.09 ± 0.32
12.81
250
71.08 ± 0.47
71.67 ± 1.20
125
66.90 ± 0.96
66.40 ± 0.25
62.50
61.35 ± 0.51
61.58 ± 1.12
31.25
57.40 ± 0.76
56.65 ± 1.34
BW3
500
70.56 ± 1.06
36.82
83.03 ± 0.48
15.93
250
64.90 ± 0.45
76.90 ± 0.48
125
58.40 ± 0.82
71.79 ± 0.63
62.50
53.33 ± 0.66
66.67 ± 0.61
31.25
48.42 ± 0.43ns
57.69 ± 0.77
Ascorbic acid
500
87.08 ± 0.47
6.84
90.65 ± 1.32
7.10
250
82.40 ± 0.20
84.56 ± 0.45
125
77.61 ± 0.43
79.52 ± 0.66
62.50
75.45 ± 0.90
73.22 ± 1.28
31.25
63.89 ± 0.20
68.42 ± 0.43
All values are taken as mean ± SEM (n = 3), and two-way ANOVA followed by bonferroni test were followed. Values are significantly different as compared to the standard drug; ,,, and ns: not significant.
